Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout  

Shionogi's acquisition of IntraBio would expand its rare disease portfolio following the recent acquisition of ALS drug, Radicava.

Latest news

Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal

Alector’s approach combines an engineered GCase with the biotech’s blood-brain barrier delivery platform.

Scientists claim Nobel Prize for approach behind light-activated gene therapy  

The Nobel Prize committee says that optogenetics will lay the foundations for a new era in neuroscience, while pharma explores the method’s vision-restoring potential.

CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug  

The pair will work together to progress lixudebart across multiple rare kidney and liver diseases.

Lilly deepens ties with Gate Bioscience in $870m deal expansion 

Lilly is continuing to bet on the molecular gate approach, which Gate says could create therapies targeting hard-to-drug proteins.

AstraZeneca opens new R&D centre in Cambridge, US

Combined with the AstraZeneca's genomic medicine facility, the site will accommodate around 2,000 researchers and scientists.

Pacira partners with Molteni for Exparel commercialisation

The companies expect the first commercial sale under the partnership to occur in 2027.